Mucofluid (Mesna)

Mesna, the active ingredient in Mucofluid, is a thiol‑containing chemoprotective agent presented as a sterile solution for Endotracheopulmonary use. It binds the urotoxic metabolite acrolein generated during cyclophosphamide or ifosfamide therapy, thereby reducing the risk of hemorrhagic cystitis in patients undergoing these chemotherapeutic regimens.

GNH USA supplies Mucofluid as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, with distribution across EU and other regulated markets. The company adheres to stringent quality standards and provides regulatory documentation for each batch.

Mesna is employed as a chemoprotective adjuvant in oncology protocols to mitigate the urotoxic effects of certain alkylating chemotherapeutic agents, primarily cyclophosphamide and ifosfamide.

Hemorrhagic cystitis: prevents bladder inflammation, bleeding, dysuria, and associated urinary symptoms that can arise during cyclophosphamide or ifosfamide chemotherapy, thereby preserving patient quality of life. Urotoxicity prevention: diminishes overall urinary tract toxicity, reduces risk of renal impairment, and supports renal function during high‑dose cyclophosphamide or ifosfamide treatment courses. Adjunctive therapy: administered alongside adequate hydration and diuresis protocols to further lower the incidence and severity of bladder toxicity in patients receiving cyclophosphamide or ifosfamide.

Mesna may be associated with a range of adverse reactions, which are generally classified by frequency.

Common Side Effects: - Nausea: mild to moderate discomfort in the stomach. - Vomiting: occasional episodes, usually self‑limited. - Headache: transient and mild. - Rash: localized skin irritation or erythema. - Mild hypotension: temporary drop in blood pressure without severe symptoms.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergy requiring immediate medical attention. - Pulmonary edema: fluid accumulation in the lungs, presenting with shortness of breath. - Hemolysis: destruction of red blood cells leading to anemia. - Severe hypotension: marked blood pressure reduction causing dizziness or fainting. - Renal failure: impaired kidney function requiring monitoring.

When using Mesna, clinicians should consider several safety measures to minimize risk. - Renal function monitoring: assess baseline and periodic creatinine levels. - Hypersensitivity assessment: discontinue if signs of allergic reaction appear. - Dose adjustment: modify in patients with existing renal impairment. - Concomitant urotoxic agents: avoid or closely monitor use with other nephrotoxic drugs. - Adequate hydration: ensure patients receive sufficient fluid intake during therapy. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Mesna can interact with other medicines, influencing its protective effect or increasing toxicity.

Major Interactions (Avoid): - Nephrotoxic drugs (e.g., aminoglycosides): may amplify renal injury. - Other sulfhydryl donors (e.g., N‑acetylcysteine): can interfere with acrolein binding. - Strong oxidizing agents (e.g., hydrogen peroxide solutions): may reduce Mesna's efficacy.

Moderate Interactions (Monitor Closely): - Loop diuretics: monitor electrolytes and fluid balance. - Antihypertensives: observe blood pressure for additive hypotensive effects.